InVisionFirst®-Lung, a ctDNA NGS liquid biopsy testing 36 genes relevant to the care of patients with advanced NSCLC

InVisionFirst-Lung® is available world-wide for both commercial and research use. In the US, InVisionFirst-Lung is now covered for Medicare patients with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.

36 gene panel including NSCLC markers

Support the prognosis and therapeutic decisions in patients diagnosed with NSCLC


Alterations associated with:
a) an FDA approved drug for another tumor type,
b) inclusion or exclusion criteria for clinical trials and/or,
c) indicators for resistance to therapy.


SNVs + Indels - Hotspot Regions
Fusions + SNVs + Indels
CNVs + SNVs + Indels

8 actionable genes relevant to advanced NSCLC  in a panel of 36 genes

  • EGFR, ALK, ROS1 and BRAF for FDA-approved targeted therapies
  • MET and ERBB2 (HER2) as recommended by CAP/AMP/ASCO/IASLC guidelines
  • KRAS and STK11 for prognostic and therapeutic value as described in clinical literature

Largest prospective molecular diagnostics study in NSCLC published up to date in JCO Precision Oncology

98% concordance

observed with matched tissue profiling

InVisionFirst-Lung provided access to comprehensive genetic profiling (CGP) when tissue was not available

26% more actionable alterations

detected versus standard-of-care tissue testing

Our technology brings high sensitivity and specificity to drive appropriate treatment choice

InVision® Platform can detect single nucleotide variants (SNVs), small insertions and deletions (InDels), copy number variant (CNVs), and structural variants (SV) such as fusions from plasma cell free DNA (cfDNA) with a detection range as low as 0.1% variant allele fraction with a mean read depth of 70,000.

Click here for InVisionFirst®-Lung clinical validation results and clinical utility data.

Results within 7 calendar days from blood draw

  • Test results are delivered through a secure Clinician Portal
  • The report includes genetic alterations and corresponding recommended therapeutics, such as assessment of predicted response to treatments and available to currently enrolling clinical trials
  • This report can be easily exported and added to most electronic health records (EHRs)

InVisionFirst®-Lung can help at different stages:


At Diagnosis*

  • When results for EGFR single nucleotide variants (SNVs) and insertions and deletions (indels); rearrangements in ALK and ROS1; and SNVs for BRAF are not available AND
  • When tissue-based CGP is infeasible (i.e. quantity not sufficient (QNS) for tissue-based CGP or invasive biopsy is medically contraindicated).


At Progression*

  • For patients progressing on or after chemotherapy or immunotherapy who have not been tested for EGFR SNVs and indels; rearrangements in ALK and ROS1; and SNVs for BRAFs, and for whom tissue-based CGP is infeasible; OR
  • For patients progressing on EGFR tyrosine kinase inhibitors (TKIs).

* If no genetic alteration is detected by InVisionFirst®-Lung or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered

Advocating for patients with advanced NSCLC

Inivata offers the InVision® Access Program, a supportive patient assistance program for eligible patients, to help at every step along the way.